Stock COMBI COMBIGENE AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials CombiGene AB

Equities

COMBI

SE0016101935

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm
Other stock markets
 12:00:00 2024-07-05 pm EDT 		5-day change 1st Jan Change
3.1 SEK +0.65% Intraday chart for CombiGene AB +6.90% +15.24%
Jun. 24 CombiGene Enters into A License Agreement with Spark for the Epilepsy Project CG01 CI
May. 27 CombiGene Appoints New Chief Scientific Officer MT

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 79.45 71.23 157.3 225.7 180.9 53.27
Enterprise Value (EV) 1 47.65 63.07 108.4 88.99 49.11 -48.17
P/E ratio -3.15 x -3.58 x -4.17 x 9.42 x -29.4 x -1.49 x
Yield - - - - - -
Capitalization / Revenue 21.6 x 4.75 x 14.5 x 2.48 x 6.3 x 7.6 x
EV / Revenue 12.9 x 4.21 x 10 x 0.98 x 1.71 x -6.87 x
EV / EBITDA - -3,652,011 x -4,447,440 x 3,837,652 x -2,828,183 x 1,339,081 x
EV / FCF 10.7 x -5.89 x -3.73 x 6.84 x -4.04 x 2.57 x
FCF Yield 9.31% -17% -26.8% 14.6% -24.7% 39%
Price to Book 3.88 x 3.86 x 2.2 x 1.43 x 1.19 x 0.46 x
Nbr of stocks (in thousands) 2,580 3,253 11,464 19,801 19,801 19,801
Reference price 2 30.80 21.90 13.72 11.40 9.135 2.690
Announcement Date 4/25/19 6/8/20 5/4/21 4/27/22 4/26/23 4/26/24
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 3.686 14.99 10.83 91.15 28.73 7.008
EBITDA - -17.27 -24.37 23.19 -17.36 -35.98
EBIT 1 -13.23 -18.44 -26.87 22.89 -17.66 -36.31
Operating Margin -358.87% -123.02% -248.12% 25.11% -61.47% -518.05%
Earnings before Tax (EBT) 1 -13.15 -17.93 -29.55 20.96 -6.157 -35.67
Net income 1 -13.15 -17.6 -29.38 20.96 -6.157 -35.67
Net margin -356.6% -117.46% -271.37% 23% -21.43% -508.92%
EPS 2 -9.778 -6.118 -3.287 1.210 -0.3109 -1.801
Free Cash Flow 1 4.437 -10.71 -29.05 13.01 -12.14 -18.78
FCF margin 120.35% -71.47% -268.34% 14.28% -42.27% -267.92%
FCF Conversion (EBITDA) - - - 56.12% - -
FCF Conversion (Net income) - - - 62.07% - -
Dividend per Share - - - - - -
Announcement Date 4/25/19 6/8/20 5/4/21 4/27/22 4/26/23 4/26/24
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 31.8 8.17 48.9 137 132 101
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 4.44 -10.7 -29.1 13 -12.1 -18.8
ROE (net income / shareholders' equity) -97.5% -88% -64.4% 18.3% -3.97% -26.6%
ROA (Net income/ Total Assets) -38.2% -29.2% -27.3% 11.6% -6.81% -16.3%
Assets 1 34.39 60.29 107.8 180 90.47 219.1
Book Value Per Share 2 7.930 5.680 6.230 7.990 7.680 5.880
Cash Flow per Share 2 12.30 4.660 4.270 6.910 6.660 5.120
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 4/25/19 6/8/20 5/4/21 4/27/22 4/26/23 4/26/24
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
COMBIGENE AB Stock CombiGene AB
+15.24% 5.85M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+16.61% 122B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+17.75% 112B
ARGENX SE Stock argenx SE
+17.23% 25.91B
BIONTECH SE Stock BioNTech SE
-24.11% 19.33B
GENMAB A/S Stock Genmab A/S
-18.56% 16.17B
BEIGENE, LTD. Stock BeiGene, Ltd.
-18.47% 15.56B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-47.75% 14.65B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+57.35% 14.34B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.62% 14B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. COMBI Stock
  4. Financials CombiGene AB